Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease - Trial NCT05422092
Access comprehensive clinical trial information for NCT05422092 through Pure Global AI's free database. This phase not specified trial is sponsored by First Affiliated Hospital Xi'an Jiaotong University and is currently Not yet recruiting. The study focuses on Type 2 Diabetes Mellitus With Complication. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
First Affiliated Hospital Xi'an Jiaotong University
Timeline & Enrollment
N/A
Sep 20, 2022
Dec 01, 2023
Primary Outcome
Plasma cholesteryl ester transfer protein(CETP) concentration in ug/mL,The activity of CEPT in pmol/mL/min
Summary
Type 2 diabetes mellitus (T2DM) is always accompanied with nonalcoholic fatty liver disease
 (NAFLD).This prospective, randomized controlled intervention study was designed to reveal the
 potential clinical application and underlying mechanisms of canagliflozin in the treatment of
 type 2 diabetes combined with nonalcoholic fatty liver disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05422092
Non-Device Trial